"aRigen Pharmaceuticals, Inc. - Product Pipeline Review - 2013" Published

Fast Market Research recommends "aRigen Pharmaceuticals, Inc. - Product Pipeline Review - 2013" from Global Markets Direct, now available

Logo

Boston, MA -- (SBWire) -- 10/14/2013 --Global Market Direct's pharmaceuticals report, "aRigen Pharmaceuticals, Inc. - Product Pipeline Review - 2013" provides data on the aRigen Pharmaceuticals, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, aRigen Pharmaceuticals, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from aRigen Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct's team.

View Full Report Details and Table of Contents

Scope

- aRigen Pharmaceuticals, Inc. - Brief aRigen Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of aRigen Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of aRigen Pharmaceuticals, Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the aRigen Pharmaceuticals, Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to Get This Report

- Evaluate aRigen Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of aRigen Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the aRigen Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with aRigen Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of aRigen Pharmaceuticals, Inc. and identify potential opportunities in those areas.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- aRigen Pharmaceuticals, Inc. - Product Pipeline Review - 2012
- Spectrum Pharmaceuticals, Inc. - Product Pipeline Review - 2013
- Isis Pharmaceuticals, Inc. - Product Pipeline Review - 2013
- Astex Pharmaceuticals, Inc. - Product Pipeline Review - 2013
- Regeneron Pharmaceuticals, Inc. - Product Pipeline Review - 2013
- Millennium Pharmaceuticals, Inc. - Product Pipeline Review - 2013
- Inovio Pharmaceuticals, Inc. - Product Pipeline Review - 2013
- AVEO Pharmaceuticals, Inc. - Product Pipeline Review - 2013
- Ligand Pharmaceuticals, Inc. - Product Pipeline Review - 2013
- Progen Pharmaceuticals Limited - Product Pipeline Review - 2013

Media Relations Contact

Bill Thompson
Director of Marketing
800-844-8156
http://www.fastmr.com

View this press release online at: http://rwire.com/349990